Overview

Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection

Status:
Completed
Trial end date:
2017-06-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with one of the most commonly prescribed glucagon-like peptide 1 receptor agonist (GLP-1 RA) exenatide. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when administered with exenatide injection.
Phase:
Phase 1
Details
Lead Sponsor:
Theracos
Treatments:
Bexagliflozin
Exenatide